Unjustifiable Delays In Generic Competition? Biopharma Contends There Is No Problem
Executive Summary
As Congress prepares to again debate patent reforms, brand industry says allegations of ‘patent thickets’ and extended market exclusivity are based on inaccurate or misleading data. They assert there is no need for PTO and FDA to institute systemic policy changes.
You may also be interested in...
US FDA Set To Begin Training Patent Examiners This Spring
Prompted by an Executive Order on drug price competition, the cross-agency training aims to ensure that the Patent and Trademark Office is aware of all information that FDA makes available.
The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge
First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.
AbbVie Suggests Humira Will Retain Leading Position In 2023
AbbVie CEO Richard Gonzalez has set out his expectations for Humira in 2023, with the US market on the cusp of biosimilar competition from multiple adalimumab rivals.